Lord’s Mark Enters Global MedTech Arena with 153 US FDA Registrations

Lord’s Mark Enters Global MedTech Arena with 153 US FDA Registrations

Major Regulatory Milestone:
Lord’s Mark Industries Ltd has achieved a significant milestone by securing registration from the United States Food and Drug Administration (US FDA) for 153 orthosurgical products, placing the company among a select group of Indian manufacturers with extensive US FDA‑listed portfolios.

Enhanced Global Positioning:
This achievement elevates the company’s stature within the global medical device manufacturing sector, particularly for Indian firms aiming to compete in highly regulated international markets.

Product Range Details:
The US FDA‑listed portfolio covers a wide range of orthosurgical and rehabilitation items, including but not limited to: orthopaedic braces; spinal and cervical supports; knee and ankle braces under the Lord’s Activeguard brand; compression stockings; hernia belts; disinfectant and cleansing wipes; tennis elbow supports; elastic adhesive bandages; abdominal support devices; and products designed for post‑surgical rehabilitation.

Manufacturing Standards:
All FDA‑listed products are manufactured in Lord’s Mark’s globally compliant production ecosystem, which is structured to meet rigorous regulatory requirements. The company’s manufacturing operations are supported by internationally benchmarked protocols, quality management systems, validated processes, traceability mechanisms and compliance frameworks aligned with US FDA expectations.

Leadership Commentary:
Sachidanand Upadhyay, Managing Director of Lord’s Mark Industries Ltd, highlighted that this recognition reflects the company’s commitment to producing world‑class medical devices from India and underscores the strength of its Silvassa manufacturing platform and long‑term vision to position Indian‑made healthcare solutions on the global stage.

International Market Access:
With these registrations, Lord’s Mark is better placed to expand into regulated global markets, including the United States, Latin America and the Middle East, where demand for cost‑effective yet regulation‑compliant orthopaedic products is growing.

Export and Partnership Opportunities:
The company can now pursue institutional supplies, hospital partnerships and distributor‑led exports more effectively, enhancing its global distribution footprint.

US Subsidiary Role:
Through its US‑based arm, Lord’s Mark Global LLC, the company joins a small cohort of Indian medtech firms with established product listings by the US FDA, thereby contributing to India’s expanding presence in the international medical technology value chain.

Source: https://www.hindustantimes.com/genesis/lords-mark-becomes-one-of-the-companies-with-153-us-fda-listed-products-101768457978450.html